HC Wainwright began coverage on shares of Aligos Therapeutics (NASDAQ:ALGS – Free Report) in a research report released on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $75.00 price target on the stock.
Aligos Therapeutics Price Performance
NASDAQ ALGS opened at $13.75 on Monday. The stock’s 50 day simple moving average is $12.14 and its 200-day simple moving average is $17.20. The company has a market cap of $1.07 billion, a PE ratio of -10.74 and a beta of 2.18. Aligos Therapeutics has a 1-year low of $8.70 and a 1-year high of $30.00.
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative return on equity of 144.16% and a negative net margin of 783.72%. The company had revenue of $1.06 million for the quarter. During the same quarter in the previous year, the business posted ($10.75) EPS. On average, equities research analysts anticipate that Aligos Therapeutics will post -0.73 EPS for the current fiscal year.
Institutional Inflows and Outflows
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Further Reading
- Five stocks we like better than Aligos Therapeutics
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Stock Sentiment Analysis: How it Works
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.